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Background Systemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in 
our area, presents hematologic manifestations in approximately 70% of cases
1
. Some of them are very 
rare so there are no large series whose analysis could provide relevant information. 
 
Objectives To study the characteristics of patients with Hemophagocytic Syndrome (HS) in a large 
sample of SLE patients. 
 
Methods SLE patients from RELESSER database were studied. We analysed SLE manifestations present 
at 12 different domains (mucocutaneous, renal, musculoskeletal, constitutional, hematologic, vascular, 
cardiac, respiratory, neuropsychiatric, gastrointestinal, ophthalmic and serological) before, during and 
after HS diagnosis and until the last available assessment. We also studied activity (SELENA-SLEDAI) 
and damage (SLICC/ACR DI) indices at those moments.We evaluated the treatment received, HS 
recurrences and the number of deaths by this entity. 
 
Results 3,656 SLE patients (≥4 ACR criteria) from 45 Rheumatology Units across Spain were studied. 
Seven patients (<0.5%) with HS were identified. 71.4% were women, with a mean age (± S.D.) at SH 
diagnosis of 35.1 (± 17.1) years. In 5 of the 7 cases the HS occurred 115.5 (± 162.9) months after SLE 
diagnosis. In the other 2 cases the diagnosis of both entities was simultaneous. The main triggers of HS 
were infections, followed by SLE activity flares. At the time of HS diagnosis, they had high SLE activity 
with a mean SLEDAI score of 13.1 (± 11.3) and 1.4 (± 2.3) SDI score. 
Clinically, 100% of the patients presented fever and alterations of the liver profile, 85.8% cytopenias and 
71.5% dermatological manifestations. Respiratory manifestations and hemolytic anemia were present in 
57.2% of the cases, both; lymph nodes and coagulopathy in 42.9%. Hepatomegaly was detected in 28.6%, 
as well as neuropsychiatric, digestive and renal manifestations. Splenomegaly was detected in 14.3%. The 
mean hemoglobin level was 8.6 (± 1.1) g/dl, platelets 85,585 (± 83,390)/mm
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, ferritin 7,410 (± 6,470) 
ng/ml and triglycerides 404.7 (± 235.6) mg/dl. All patients were admitted and undergonebone marrow 
study, requiring a mean of 2.2 (± 1.5) treatment lines, using 2.8 (± 1.7) drugs. One patient died during the 
HS episode by the HS itself and another 2 patients had 2 and 3 recurrences, respectively. 
  
 
 
Conclusions HS is a rare life-threatening SLE manifestation. It must be suspected in SLE patients with 
persistent fever who do not respond to antibiotics, cytopenias and evidence of multiorgan involvement. 
Relapses and death are common in HS associated to SLE. 
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